Campen DH - Search Results

1

Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation.

Campen DH, Horwitz DA, Quismorio FP Jr, Ehresmann GR, Martin WJ. Campen DH, et al. Arthritis Rheum. 1988 Nov;31(11):1358-64. doi: 10.1002/art.1780311103. Arthritis Rheum. 1988. PMID: 3263865

2

Candida septic arthritis in rheumatoid arthritis.

Campen DH, Kaufman RL, Beardmore TD. Campen DH, et al. J Rheumatol. 1990 Jan;17(1):86-8. J Rheumatol. 1990. PMID: 2179552 Review.

3

Surgical procedures in the management of Takayasu's arteritis.

Weaver FA, Yellin AE, Campen DH, Oberg J, Foran J, Kitridou RC, Lee SE, Kohl RD. Weaver FA, et al. Among authors: campen dh. J Vasc Surg. 1990 Oct;12(4):429-37; discussion 438-9. doi: 10.1067/mva.1990.23183. J Vasc Surg. 1990. PMID: 1976828

4

Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug.

Cheetham TC, Chan J, Benson V, Richmond C, Levin E, Campen D. Cheetham TC, et al. Am J Manag Care. 2005 Sep;11(9):546-52. Am J Manag Care. 2005. PMID: 16159044 Free article.

5

Myocardial Infarction and Its Association with the Use of Nonselective NSAIDs: A Nested Case-Control and Time-to-Event Analysis.

Cheetham TC, Graham DJ, Campen D, Hui R, Spence M, Levy G, Shoor S. Cheetham TC, et al. Perm J. 2008 Winter;12(1):16-22. doi: 10.7812/TPP/07-081. Perm J. 2008. PMID: 21369507 Free PMC article.

6

Relationship of clinical factors to the use of Cox-2 selective NSAIDs within an arthritis population in a large HMO.

Bull SA, Conell C, Campen DH. Bull SA, et al. Among authors: campen dh. J Manag Care Pharm. 2002 Jul-Aug;8(4):252-8. doi: 10.18553/jmcp.2002.8.4.252. J Manag Care Pharm. 2002. PMID: 14613417

7

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.

Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA. Graham DJ, et al. Lancet. 2005 Feb 5-11;365(9458):475-81. doi: 10.1016/S0140-6736(05)17864-7. Lancet. 2005. PMID: 15705456

8

Kaiser Permanente's prescription drug benefit.

Levine S, Campen D, Millares M, Barrueta A. Levine S, et al. Health Aff (Millwood). 2000 Mar-Apr;19(2):185-90. doi: 10.1377/hlthaff.19.2.185. Health Aff (Millwood). 2000. PMID: 10718032 Review. No abstract available.

9

The bleeding edge of decision making in managed health care--Kaiser-Permanente's model for formulary development.

Campen D. Campen D. Value Health. 2002 Sep-Oct;5(5):383-9. doi: 10.1046/J.1524-4733.2002.55001.x. Value Health. 2002. PMID: 12201855 Free article. No abstract available.

10

Cardiac mechanoenergetics replicated by cross-bridge model.

Vendelin M, Bovendeerd PH, Arts T, Engelbrecht J, van Campen DH. Vendelin M, et al. Among authors: van campen dh. Ann Biomed Eng. 2000 Jun;28(6):629-40. doi: 10.1114/1.1305910. Ann Biomed Eng. 2000. PMID: 10983709

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23 results

Search Page